Targets › RPODC
1 program from 1 company in 1 trial: 1 Phase 3; Immunology; next expected readout Jun 2030.
Open in Phaseline: the race on RPODC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| McGill University Health Centre/Research Institute of the McGill University Health Centre | Fidaxomicin DNA-directed RNA polymerase inhibitor | RPODC | Phase 3 | Clostridia Difficile Colitis | Jun 2030 |
Clostridia Difficile Colitis (1)
small molecule (1)
McGill University Health Centre/Research Institute of the McGill University Health Centre (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.